AstraZeneca meets guidance as strong performance of new medicines deliver boost

Writer, Stock Market Wire
Thursday, February 14, 2019 - 07:28

AstraZeneca said Thursday a 'strong' fourth quarter led by performance of new medicines underscored its return to growth as the drugmaker met its guidance.

For the 12 months to 31 December, revenue fell 2% to $22.1bn and product sales rose 4% to $21.05bn, which was in line with guidance for low-single-digit growth. While earnings per share fell 19% to $3.46 a share, toward the upper end of guidance for earnings of $3.30 to $3.50 a share.

The in line earnings and product sales were driven by a 'strong' fourth quarter amid strong performance from new drugs, the company said.

Product sales rose 8% to $5.77bn for the quarter, from a year earlier, and core earnings were up 22% to $1.58 a share.

Growth was the led by the performance of new drugs -- especially those for cancer – as oncology sales grew 50% to $6.04bn for the year.

The company declared a second interim dividend of $1.90 per share, taking the unchanged full-year dividend per share to $2.80.

'Closing the year with another strong quarter, our performance confirmed that AstraZeneca has returned to growth,' said Pascal Soriot, Chief Executive Officer.

'Our new medicines performed particularly well across the therapy areas and the Emerging Markets business went from strength to strength'

For 2019, the company said it would target core earnings per share of $3.50 to $3.70, and full-year product sales are expected to increase in high single-digit percentage, at constant currency rates.

Core operating profit in 2019 was anticipated to increase, ahead of product sales, by a mid-teens percentage compared with a year earlier. While core operating expenses were also expected to increase by a low single-digit percentage.

Related content

Stocks, bonds and sterling react as markets hope for break in Brexit deadlock

Markets had been taking their lead from the opinion polls and pricing in a clear-cut victory for the Conservative Party and that is what they...

Fri, 13/12/2019 - 13:49

Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC

Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 8400p (from 8300p).

Broker Forecasts data provided...

Thu, 12/12/2019 - 08:30

AstraZeneca non-small cell lung cancer drug receives marketing rights in China

AstraZeneca said that its drug to treat patients with non-small cell lung cancer had received marketing authorisation from China's National Medical Products Administration.

The approval...

Thu, 12/12/2019 - 07:45

AstraZeneca, Daiichi Sankyo report positive trial results for breast cancer treatment

AstraZeneca and Daiichi Sankyo released positive data from the a trial of a treatment for breast cancer.

The phase-two trial studied the effects of trastuzumab...

Wed, 11/12/2019 - 13:05

AstraZeneca agrees to sell rights to schizophrenia, bipolar disorder drugs to Cheplapharm for up to $41m

AstraZeneca said it had agreed to sell the commercial rights to its schizophrenia and bipolar disorder drugs in the US and Canada to Cheplapharm Arzneimittel...

Tue, 03/12/2019 - 08:04